Why Did Zentalis Pharmaceuticals Inc. (ZNTL) Plunge 11.33%?

On June 5, 2025, Zentalis Pharmaceuticals Inc. (ZNTL) experienced a significant drop of 11.33% in pre-market trading, reflecting a notable decline in investor sentiment.

Analysts have recently weighed in on Zentalis Pharmaceuticals, with Wedbush reaffirming a "neutral" rating and setting a $4.00 price target. Meanwhile, HC Wainwright reiterated a "buy" rating with a $10.00 price objective. The average rating among analysts is "Hold," with an average target price of $8.24.

Insider activity has also been noted, with Director Scott Dunseth Myers acquiring 21,000 shares at an average price of $1.40 per share, increasing his ownership by 8.07%. This purchase was disclosed in a filing with the Securities and Exchange Commission.

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for various cancers. Its pipeline includes ZN-c3, an inhibitor of WEE1, which is being tested in multiple clinical trials for different cancer indications.